2017-2020年南京医科大学附属脑科医院第二类精神药品使用情况分析

目的 探讨2017—2020年南京医科大学附属脑科医院第二类精神药品的使用情况与发展趋势。方法 采用回顾性研究方法，对南京医科大学附属脑科医院2017—2020年第二类精神药品的销售金额、用药频度（DDDs）、日均费用（DDC）、排序比（B/A）等进行统计分析。结果 将使用的第二类精神药品品种按化学结构分类，各分类金额构成比基本稳定。巴比妥类占比最低，苯二氮类和非苯二氮类的销售金额呈逐年上升趋势。非苯二氮类的DDDs构成比呈微增长趋势，苯二氮类和巴比妥类的DDDs构成比呈微下降趋势。第二类精神药品销售金额的前3位保持稳定，分别为唑吡坦、劳拉西泮、佐匹克隆。唑吡坦、佐匹克隆、劳拉西泮的DDDs始终位于前3。2017—2020年第二类精神药品的DDC保持基本稳定，略有上涨。大部分药品的B/A在0.8～1.2，比较明显的是奥沙西泮的B/A<0.8，艾司唑仑、阿普唑仑、硝西泮的B/A>1.2。结论 南京医科大学附属脑科医院第二类精神药品结构合理，非苯二氮类药物使用逐渐增多。

Application analysis on the second class of psychotropic drugs in The Affiliated Brain Hospital of Nanjing Medical University from 2017 to 2020

Objective To evaluate the application situation and development tendency of the second class psychotropic drugs in the Affiliated Brain Hospital of Nanjing Medical University from 2017 to 2020. Methods Using the consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) as the indicators, to retrospectively analyze the application of the second class psychotropic drugs. Results The second class psychotropic drugs were classified according to chemical structure, and the sum composition ratio of each category was basically stable. The proportion of barbiturates was the lowest, and the consumption sum of benzodiazepines and non-benzodiazepines increased year by year. The DDDs composition ratio of non-benzodiazepines showed a slight increase trend, while that of benzodiazepines and barbiturates showed a slight decrease trend. The top 3 of consumption sum of the second class psychotropic drugs remained stable, namely, zolpidem, lorazepam and zopiclone. The DDDs of zolpidem, zopiclone and lorazepam were always in the top 3. DDC of the second class psychotropic drugs remained basically stable and increased slightly from 2017 to 2020. The B/A of most drugs ranged from 0.8 to 1.2, with the B/A of oxazepam < 0.8, and the B/A of estazolam, alprazolam and nitrazepam > 1.2. Conclusion The application structure of the second class psychotropic drugs is basically reasonable, and the use of non-benzodiazepines is increasing gradually.